Establishment and characterization of a cisplatin‑resistant human osteosarcoma cell line

Han,Tao; Zhu,Xiaoming; Wang,Julei; Zhao,Haien; Ma,Qiong; Zhao,Jian; Qiu,Xiuchun; Fan,Qingyu

doi:10.3892/or.2014.3314

Establishment and characterization of a cisplatin‑resistant human osteosarcoma cell line

Authors:
- Tao Han
- Xiaoming Zhu
- Julei Wang
- Haien Zhao
- Qiong Ma
- Jian Zhao
- Xiuchun Qiu
- Qingyu Fan
View Affiliations

Affiliations: Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China, Department of Obstetrics and Gynecology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China, Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
Published online on: July 7, 2014 https://doi.org/10.3892/or.2014.3314
Pages: 1133-1139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to establish a new cisplatin-resistant human osteosarcoma cell line and investigate its biological characteristics. The human osteosarcoma cell line SOSP-9607 was exposed to cisplatin by stepwisely increasing the concentrations in the medium to select for the drug-resistant subline, SOSP-9607/CDDP cells. The morphological features were observed using inverted microscopy. The growth curves of SOSP-9607 and SOSP-9607/CDDP cells were drawn to calculate the doubling time. FCM was also used to determine the distribution of the cell cycle. The MTT assay was performed to test the drug resistance of SOSP-9607 and SOSP-9607/CDDP cells. Transwell assay was used to examine the invasive capability of the SOSP-9607/CDDP and SOSP-9607 cells. RT-PCR was performed to determine the mRNA expression levels of drug resistance-related and apoptosis-related genes, MDR1, MRP1, MRP2, LRP, ABCG2, GST-π, Bcl-2 and Bax, in both cell lines. SOSP-9607/CDDP cells exhibited changes in morphology, proliferation rate, doubling time, cell cycle distribution and invasive capability as compared with the SOSP-9607 cells. SOSP-9607/CDDP cells were 6.24-fold resistant to cisplatin in comparison with the SOSP‑9607 cells and also exhibited cross-resistance to methotrexate and adriamycin. SOSP-9607/CDDP cells overexpressed MRP1, MRP2 and GST-π. In conclusion, SOSP-9607/CDDP cells are invaluable tools with which to study the resistance of anticancer drugs and to identify the methods to overcome resistance.

View Figures

View References

1	Gorlick R and Khanna C: Osteosarcoma. J Bone Miner Res. 25:683–691. 2010. View Article : Google Scholar
2	Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar
3	Negoro K, Yamano Y, Fushimi K, Saito K, Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, Tanzawa H and Fujita S: Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol. 30:1325–1332. 2007.PubMed/NCBI
4	Chen X, Yang TT, Wang W, Sun HH, Ma BA, Li CX, Ma Q, Yu Z and Fan QY: Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology. 61:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
5	Shibata K, Umezu T, Sakurai M, Kajiyama H, Yamamoto E, Ino K, Nawa A and Kikkawa F: Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Gynecol Obstet Invest. 71:104–111. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
7	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
8	Asada N, Tsuchiya H, Ueda Y and Tomita K: Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line. Anticancer Res. 18:1765–1768. 1998.PubMed/NCBI
9	Maraldi NM, Zini N, Santi S, Scotlandi K, Serra M and Baldini N: P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biol Cell. 91:17–28. 1999. View Article : Google Scholar : PubMed/NCBI
10	Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y and Tsuneyoshi M: Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep. 7:859–866. 2000.PubMed/NCBI
11	Niu BH, Wang JJ, Xi Y and Ji XY: The establishment and characterization of adriamycin-resistant cell lines derived from Saos-2. Med Sci Monit. 16:BR184–BR192. 2010.PubMed/NCBI
12	Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
13	Wang C, Guo LB, Ma JY, Li YM and Liu HM: Establishment and characterization of a paclitaxel-resistant human esophageal carcinoma cell line. Int J Oncol. 43:1607–1617. 2013.PubMed/NCBI
14	Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar : PubMed/NCBI
15	Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N and Taniguchi T: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 451:1116–1120. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R and Baselga J; Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 18:522–528. 2007. View Article : Google Scholar : PubMed/NCBI
17	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
18	Li J, Li ZN, Du YJ, Li XQ, Bao QL and Chen P: Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer. 10:414–421. 2009. View Article : Google Scholar
19	Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
20	Liedert B, Materna V, Schadendorf D, Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol. 121:172–176. 2003. View Article : Google Scholar : PubMed/NCBI
21	Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M and Doki Y: Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 104:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chen HH and Kuo MT: Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs. 2010:4309392010. View Article : Google Scholar
23	Lai GM, Moscow JA, Alvarez MJ, Fojo AT and Bates SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer. 49:688–695. 1991. View Article : Google Scholar : PubMed/NCBI
24	Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T and Isaka K: Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumor Biol. 32:399–408. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 17:463–468. 1992. View Article : Google Scholar : PubMed/NCBI
26	Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A and Kroemer G: Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene. 27:4221–4232. 2008. View Article : Google Scholar : PubMed/NCBI
27	Jain HV and Meyer-Hermann M: The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res. 71:705–715. 2011. View Article : Google Scholar : PubMed/NCBI